Status epilepticus occurs in more than 50,000 people in the United Sta
tes each year and should be considered a neurologic emergency. A varie
ty of drugs are used to treat status epilepticus, including IV benzodi
azepines, phenytoin, and barbiturates. They are all short of being ide
al, primarily because of difficulties with administration or associate
d toxicity. Fosphenytoin, a prodrug and phosphate ester of phenytoin,
was developed to overcome the drawbacks associated with IV phenytoin.
With its efficacy, safety, and ease of administration, fosphenytoin is
a valuable option for the treatment of status epilepticus.